Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan in NEPC After Platinum-based Chemotherapy
NCT07639086Phase 2Not yet recruiting
- Sponsor
- Virginia Commonwealth University
- Start
- Aug 2026
- Primary completion
- Mar 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in neuroendocrine prostate cancer (NEPC), sponsored by Virginia Commonwealth University. Primary endpoint: Objective Response Rate up to 30 months. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
neuroendocrine prostate cancer (NEPC)
Beyond the preview
Go deeper on NCT07639086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07639086.